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Many investigators have generated great interest in tumor stem cells (TSCs) as 
therapeutic targets; however, cancer therapies targeting TSCs are limited. A 
drawback is that TSC markers are often shared by normal stem cells (NSCs)1-4, 
and thus, therapies that target these markers may cause severe injury to normal 
tissues. 
To identify a TSC-specific marker, we focused on doublecortin-like kinase 1 
(Dclk1). Dclk1 was reported as a candidate NSC marker in the gut5,6, but recent 
reports have suggested it as a marker of differentiated cells (e.g., Tuft cells)7,8. 
By lineage tracing experiments, we here revealed that Dclk1 does not mark 
NSCs in the intestine but it marks TSCs that continuously produce tumor 
progeny in the polyps of ApcMin/+ mice. Specific ablation of Dclk1+ TSCs resulted 
in a dramatic regression of polyps without apparent damage to the normal 
intestine. Our data demonstrate the potential of a therapy for colorectal cancer 
(CRC) based on targeting Dclk1+ TSCs. 
 
Main body 
Recent advances in stem cell biology have identified intestinal NSC markers, 
such as Lgr5, Bmi1, and CD1333,9,10. Accumulating evidence also supports the 
existence of TSCs1,2,11-16, which resemble NSCs in their capacity for self-renewal 
and continuously replenishing tumor progeny17,18. Previously reported TSC 
markers are shared by NSCs in the intestine1-4; thus, identifying TSC-specific 
markers is an important challenge. 
Dclk1 was reported as a putative intestinal NSC marker located at the “+4 
position,” just above the Paneth cells5,6,19. However, recent reports have 
suggested that Dclk1 marks Tuft cells7,8, and it remains unclear whether Dclk1 
marks NSCs. Furthermore, the presence of Dclk1+ cells in murine intestinal 
tumors and human CRCs has been reported6,20; however, their potential 
capacity for tumorigenesis remains also unknown. 
In this study, we confirmed that Dclk1+ cells were scattered in the intestinal 
epithelium, but were most frequently observed at the lower crypt in normal 
murine and human intestines as previously reported6,19 (Supplementary Fig. 1a, 
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b, d). Dclk1+ cells were also scattered in the intestinal polyps of ApcMin/+ mice 
and human CRCs (Supplementary Fig. 1c, e–h).  
To investigate the stemness of Dclk1+ cells in normal intestines and during 
intestinal tumorigenesis, we generated knock-in mice by integrating a 
creERT2-IRES-EGFP cassette at the first ATG codon of Dclk1 (Dclk1creERT2/+; 
Supplementary Fig. 2). Dclk1creERT2/creERT2 mice were healthy (Supplementary 
Fig. 3), in accordance with a previous report21. As reported6,20, Dclk1+ cells were 
distinct from other epithelial cell populations (Supplementary Fig. 4). 
To test whether Dclk1 marks NSCs in the normal intestine, we performed 
tamoxifen/cre-mediated lineage tracing22,23 in the small intestine (Fig. 1a) and 
colon (Supplementary Fig. 5) of Dclk1creERT2/+; Rosa26R mice. No LacZ-labeled 
cells were detected in the absence of tamoxifen injection (data not shown). One 
day after injection, scattered LacZ-labeled blue cells were found most frequently 
at the lower crypt, in accordance with our immunohistochemical data (Fig. 1b–d). 
However, majority of blue cells shifted toward the villus tip on a daily basis, 
which was accompanied by a decrease in their numbers (Fig. 1b–e). These data 
suggest that most Dclk1+ cells originated at the lower crypt, migrated upward, 
and disappeared around the villus tip within a few weeks. We could not detect 
BrdU incorporation in Dclk1+ cells in the normal intestine (Fig. 1f, g). Collectively, 
it is suggested that Dclk1 was not a NSC marker in the normal intestine. 
Subsequently, we tested the potential stemness of Dclk1+ cells during 
regeneration after mucosal injury induced by irradiation or dextran sulfate 
sodium treatment (Supplementary Fig. 6). We found that an extremely small 
number of “blue stripes” comprised LacZ-labeled Dclk1-positive cell lineages in 
each experiment. Thus, Dclk1+ cells rarely produced progeny during mucosal 
regeneration, and their potential stemness was strictly limited. 
We then investigated whether Dclk1 marks intestinal TSCs. Surprisingly, 
lineage tracing analyses of Dclk1creERT2/+; Rosa26R; ApcMin/+ mice demonstrated 
that polyps were occupied by LacZ-labeled blue cells (“blue polyps”), with 
scattered LacZ expression in the normal intestine 7 days after tamoxifen 
injection (Fig. 2a–d, Supplementary Fig. 7). This finding highlighted a unique 
character of Dclk1-expressing cells when compared with the results of knock-in 
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mice using Lgr5, a representative intestinal NSC and TSC marker4,9,24. In 
Lgr5-EGFP-IRES-creERT2 (Lgr5creERT2/+); Rosa26R; ApcMin/+ mice, numerous 
blue stripes and blue polyps developed, comprising LacZ-labeled Lgr5-positive 
cell lineages (Fig. 2e–g). We traced LacZ expression in the polyps of 
Dclk1creERT2/+; Rosa26R; ApcMin/+ mice over time. One day after tamoxifen 
injection, 3.1% of tumor cells were LacZ labeled (Fig. 2h). Then, labeled cells at 
the polyp base expanded daily to the luminal side, and finally occupied the whole 
polyp within 5–7 days (Fig. 2i–l). This rapid renewal of the tumor epithelium was 
also observed in the polyps from Lgr5creERT2/+; Rosa26R; ApcMin/+ mice and 
BrdU-pulsed ApcMin/+ mice (Supplementary Fig. 8). Significantly, the number of 
blue polyps did not decrease by day 105 (Fig. 2m, n). ApcMin/+; Dclk1creERT2/creERT2 
mice showed the same number and size of polyps as ApcMin/+ mice, suggesting 
that insertion of the creERT2 cassette did not affect the potential role of Dclk1 
during tumorigenesis (Supplementary Fig. 9). Collectively, these data clearly 
indicated that Dclk1 marked TSCs capable of self-renewal and producing tumor 
progeny over a prolonged period. 
Next, we elucidated the character of Dclk1+ cells in the tumors. In contrast to 
the normal intestine, a small proportion of Dclk1+ tumor cells expressed 
proliferation markers, particularly at the polyp base (Fig. 3a–c; Supplementary 
Fig. 10). Lgr5 was also expressed at the polyp base, where a proportion of 
Dclk1+ tumor cells were positive for Lgr5 (Fig. 3d–g). Combined with the finding 
that Dclk1+ cell lineages appeared to be generated from Dclk1+ cells at the polyp 
base (Fig. 2h–l), we hypothesized that the Dclk1- and Lgr5-double positive cells 
located at the polyp base were candidate TSCs in ApcMin/+ mice. Importantly, few 
Dclk1+ cells exhibited apoptosis (Fig. 3h, i). This suggests that Dclk1 might 
confer an antiapoptotic property to TSCs, in accordance with a previous report25. 
We then investigated the hierarchy between Dclk1 and Lgr5. Lgr5creERT2/+; 
Catnb1lox(ex3)/+ mice, in which cre recombination stabilizes β-catenin26, 
developed numerous intestinal polyps 40 days after tamoxifen injection 
(Supplementary Fig. 11a–d), as expected27. We found that Dclk1+ tumor cells 
colocalized with Lgr5 at the base of these polyps (Supplementary Fig. 12). In 
contrast, Dclk1creERT2/+; Catnb1lox(ex3)/+ mice did not develop intestinal polyps, 
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even 45 days after injection (Supplementary Fig. 11e–g). These data suggest 
that Dclk1+ cells in the normal intestine did not transform into TSCs directly and 
that Dclk1 expression arose secondarily in Lgr5+ TSCs. 
To ensure that Dclk1+/Lgr5+ cells are bona fide TSCs, we compared the 
Dclk1−/Lgr5−, Dclk1+/Lgr5−, Dclk1−/Lgr5+, and Dclk1+/Lgr5+ tumor cell 
populations by FACS analyses. Flow cytometry showed that anti-Dclk1 staining 
agreed with Dclk1-GFP, and the knock-in cassette was restricted to Dclk1+ cells 
in the polyps of Dclk1creERT2−IRES-EGFP/+; ApcMin/+ mice (Supplementary Fig. 13a, b). 
We sorted tumor cells based on the expression of Dclk1 and Lgr5-GFP in polyps 
from Lgr5EGFP−IRES-creERT2/+; Catnb1lox(ex3)/+ mice and the proportion of 
Dclk1+/Lgr5+ tumor cells in the total Dclk1+ cells was 5.3% (Fig. 4a), in 
accordance with our immunohistochemical data. Flow cytometry demonstrated 
that the representative TSC marker CD44 and CD133 expression were highest 
in Dclk1+/Lgr5+ cells among the four cell populations (Fig. 4b, c). Dclk1+/Lgr5+ 
tumor cells also showed the highest expression of Bcl-2, a representative 
anti-apoptotic protein (Fig. 4d). Subsequently, we collected Lgr5+ tumor cells 
(Supplementary Fig. 13c), which were double-stained with antibodies against 
Dclk1 and proliferative or apoptotic markers. We occasionally observed Ki67+ 
proliferative cells in Dclk1+/Lgr5+cells, whereas we rarely detected TUNEL+ 
apoptotic cells (Fig. 4e–h). Expression of Cox-1, a Tuft cell marker, was higher in 
Dclk1+/Lgr5+ and Dclk1+/Lgr5− tumor cells (Supplementary Fig. 13d). Overall, 
these results suggest that Dclk1+/Lgr5+ cells have the potential of TSCs, with an 
antiapoptotic character28,29. 
Finally, we investigated whether targeting TSCs marked by Dclk1 could be an 
effective antitumor therapy. In Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ 
mice, cre activation induces the diphtheria toxin (DT) receptor in Dclk1+ cells, 
and administration of DT results in the death of these cells30,31 (Fig. 5a). After 
tamoxifen/DT treatment, LacZ-labeled cells disappeared from the normal 
intestine, without significant damage to organ architecture (Fig. 5b–e). Even 
after DT was administered 3 times daily for 3 days until 24 h after tamoxifen 
injection, we found no significant damage to normal tissues (Supplementary Fig. 
14). In contrast, we observed severely injured or collapsed polyps over time after 
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a single DT treatment (Fig. 5f–j). To confirm that DT specifically induced the 
apoptosis of Dclk1+ cells, we examined the apoptotic status of Dclk1+ and Dclk1− 
tumor cells after DT treatment. We observed apoptotic Dclk1+ tumor cells at 12 h 
after DT injection, though apoptotic status of Dclk1− tumor cells was not affected 
(Fig. 5k, Supplementary Figure 15a, b). At later time points, Dclk1+ tumor cells 
disappeared, and the proportion of total apoptotic cells returned to the basal 
level (Supplementary Figure 15). These data suggest that DT successfully 
eliminated Dclk1+ cells only without affecting other tumor cells. Combined with 
the finding that the turnover rate of polyps was approximately 7 days, it is 
suggested that the interruption of the tumor progeny supply by Dclk1+ TSCs 
resulted in tumor regression during this period. 
In this study, we showed that Dclk1 did not mark NSCs but marked TSCs that 
were capable of continuously producing tumor progeny in the intestine of 
ApcMin/+ mice (Fig. 6a, b). Our lineage tracing analyses showed that the intestinal 
polyps of ApcMin/+ mice had a rapid turnover rate organized by TSCs. We 
suggest that Dclk1+/Lgr5+ cells at the tumor base have a character of TSCs in a 
hierarchical system in murine intestinal adenoma, which agrees with a previous 
report that stem cell-like tumor cells exist at the base of human CRCs32. Other 
stem cell markers may substitute for Lgr5 as a partner of Dclk1 because 
Dclk1+/Lgr5+ cells had higher expression of CD44 and CD133. Even so, it is 
particularly notable that the specific ablation of Dclk1+ TSCs resulted in tumor 
regression without significant damage to normal tissues (Fig. 6c). Though we 
implemented restrictive ablation method to kill the TSCs specifically, there 
remained the possibility that DT treatment affect the immediate progeny, not 
only the TSCs because of technical limitation. However, our analysis for 
apoptosis of Dclk1+ and other tumor cells suggested that DT specifically targeted 
Dclk1+ cells and caused tumor regression. Thus, Dclk1 appeared to be a unique 
marker for distinguishing TSCs from intestinal NSCs. The similar Dclk1 
expression pattern in humans and mice (Supplementary Fig. 1) led us to 
propose the possibility of targeting Dclk1+ tumor cells for the treatment of human 
CRCs. This study provides insights into the therapeutic potential of targeting 
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FIGURE LEGENDS 
Fig. 1. Dclk1 marked postmitotic cells rather than NSCs in the intestine. 
a, Experimental strategy of tamoxifen-inducible cre-mediated cell tracking using 
Dclk1creERT2/+; Rosa26R mice. b, Representative macroscopic images of 
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LacZ-labeled blue Dclk1+ cells (black dotted circles) on days 1 (left) and 7 (right) 
after a single tamoxifen injection. c, Representative LacZ staining (black dotted 
circles) in the small intestine on days 1, 7, and 14. d, The number and 
localization of blue-labeled Dclk1+ cells per 1000 crypt-villus units after injection 
(n = 3). Crypt-villus junction (CVJ) indicated the boundary between the higher 
crypt and the villus, which was designated from histology. e, The number of 
blue-labeled Dclk1+ cells decreased on a daily basis in the intestine (n = 3). f, 
Immunofluorescent staining showed Dclk1+ cells (green) negative for BrdU (red) 
(yellow dotted box). g, BrdU-positive cells were not detected in 1000 Dclk1+ cells 
in the normal intestine. N.D., not detected. Bars, 50 µm (b, c) and 10 µm (f). 
 
Fig. 2. Dclk1 marked TSCs in the polyps of ApcMin/+ mice. 
a, Strategy for tamoxifen-inducible cre-mediated cell tracking using Dclk1creERT2/+ 
or Lgr5-EGFP-IRES-creERT2 (Lgr5creERT2/+); Rosa26R; ApcMin/+ mice. b–d, 
Macroscopic images of the small intestine and polyps (red dotted circles) in 
Dclk1creERT2/+; Rosa26R; ApcMin/+ mice 7 days after tamoxifen injection; the 
polyps turned “blue” (b). Representative magnified image (c) and coronal section 
(d) of “blue polyps.” Only scattered LacZ expression was detected in the villi (d, 
*). e–g, Macroscopic images of the small intestine and polyps (red dotted circles) 
in Lgr5creERT2/+; Rosa26R; ApcMin/+ mice 7 days after injection; most polyps and 
villi turned blue (e). Representative magnified image (f) and coronal section (g) 
of blue polyps. It was noteworthy that the villi turned blue (g, *). h–k, LacZ 
staining on days 1 (h), 3 (i), 5 (j), and 7 (k) after a single tamoxifen injection in the 
polyps of Dclk1creERT2/+; Rosa26R; ApcMin/+ mice. l, Dclk1 expression (red dotted 
circles) was observed in cells at the base of LacZ-stained polyps. m, 
Representative histology (left), macroscopic image (upper right, red dotted 
circles) and magnified view of macroscopic image (lower right) of blue polyps on 
day 105 after injection. n, The number of blue polyps had not decreased by day 
105. Bars, 2 mm (b, e, m upper right) and 50 µm (c, d, f–l, m left and lower right). 
 




a, Colocalization of BrdU (red) and Dclk1 (green) at the polyp base (yellow 
dotted box) in Dclk1creERT2/+; ApcMin/+ mice. b, BrdU-positive cells per 1000 Dclk1+ 
cells in polyps and normal mucosa were counted. A proportion of Dclk1+ cells 
was positive for BrdU in the polyps (-p), contrary to the normal mucosa (Min-m). 
c, The proportion of BrdU-positive Dclk1+ tumor cells was significantly higher at 
the polyp base. d, Immunofluorescent analysis of Lgr5 (GFP) expression in 
Lgr5creERT2/+; ApcMin/+ mice. The yellow dotted box indicates that Lgr5 (GFP, 
green)+ tumor cells positive for nuclear β-catenin (red) were located mainly at the 
polyp base. e, Colocalization of Dclk1 (red) and Lgr5 (GFP, green) at the polyp 
base (yellow dotted box). f, Lgr5 (GFP)-stained cells per 1000 Dclk1+ cells in 
polyps and normal mucosa were counted. The proportion of Dclk1+/Lgr5+ cells 
was significantly higher in polyps (-p) than in the normal mucosa (Min-m). g, The 
proportion and localization of Dclk1−/Lgr5−, Dclk1+/Lgr5−, Dclk1−/Lgr5+, and 
Dclk1+/Lgr5+ tumor cells are shown. It is noteworthy that Dclk1+/Lgr5+ cells were 
observed mainly at the polyp base. h, Immunofluorescent analysis showed that 
Dclk1+ cells (GFP, green) rarely colocalized with cleaved caspase 3 (red) (yellow 
dotted box). i, Cleaved caspase 3-stained cells per 1000 Dclk1+ cells or Dclk1− 
cells in the polyps were counted. The proportion of both cohorts is shown, 
suggesting that Dclk1+ cells were non-apoptotic. N.D., not detected. *P < 0.05. 
Bars, 50 µm. 
 
Fig. 4. Dclk1+/Lgr5+ cells had a character of TSCs in intestinal polyps. 
a, Tumor cells were sorted on the basis of Dclk1 and Lgr5 (GFP) expression in 
Lgr5creERT2/+; Catnblox(ex3)/+ mice 40 days after tamoxifen injection. The proportion 
of Dclk1+/Lgr5+ tumor cells in total Dclk1+ cells was 5.3%. The proportion of 
Dclk1+/Lgr5+ tumor cells of the total Lgr5+ cells was 2.6%. FSC, forward scatter; 
SSC, side scatter. b–d, Flow cytometry showed the expression levels of CD44 
(b), CD133 (c), and Bcl2 (d) in each population of Dclk1−/Lgr5−, Dclk1+/Lgr5−, 
Dclk1−/Lgr5+, and Dclk1+/Lgr5+ tumor cells. A higher expression of CD44, CD133, 
and Bcl2 was observed in the Dclk1+/Lgr5+ fraction compared with the other 
three. e, Sorted Lgr5+ tumor cells were double-stained with antibodies against 
Dclk1 (green) and Ki67 (red). Dclk1+/Lgr5+ cells occasionally colocalized with 
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Ki67. f, Sorted Lgr5+ tumor cells were examined by anti-Dclk1 immunostaining 
(green) and TUNEL (red). Dclk1+/Lgr5+ cells were rarely positive for TUNEL. g, 
Approximately 1 × 103 sorted Lgr5+ or Lgr5− cells were double stained against 
Dclk1 and Ki67. The proportion of Ki67-positive proliferating cells in each 
population of Dclk1−/Lgr5−, Dclk1−/Lgr5+, Dclk1+/Lgr5−, and Dclk1+/Lgr5+ tumor 
cells is shown. N.D., not detected. h, Approximately 1 × 103 sorted Lgr5+ or Lgr5− 
cells were examined by anti-Dclk1 immunostaining and TUNEL. The proportion 
of TUNEL-positive apoptotic cells in each population of Dclk1−/Lgr5−, 
Dclk1−/Lgr5+, Dclk1+/Lgr5−, and Dclk1+/Lgr5+ tumor cells is shown. Dclk1+ cell 
fractions were significantly less apoptotic than Dclk1− cell fractions. N.D., not 
detected. *P < 0.05. Bars, 10 µm. 
 
Fig. 5. Ablation of TSCs marked by Dclk1 resulted in tumor regression 
without significant damage to normal intestine. 
a, Strategy of tamoxifen and diphtheria toxin (DT)-mediated ablation of Dclk1+ 
tumor cells using Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ mice. Cre 
activation induces DT receptors in Dclk1+ cells, and administration of DT induces 
selective death of these cells. b, Schedule of specific ablation of Dclk1+ TSCs. 
To kill the Dclk1+ cells exclusively, a single DT was injected 24 h after tamoxifen 
induction. Mice were analyzed on days 1, 3, and 5 after DT injection. c, Without 
DT treatment, blue-labeled Dclk1+ cells (black dotted circles) were detected on 
day 5. d, Following DT treatment, blue-labeled cells were rarely detected. e, 
Numbers of blue-labeled cells with (DT(+)) or without (DT(–)) DT treatment on 
day 5 (n = 6). f, Without DT treatment, scattered blue Dclk1+ tumor cells were 
observed including cells near the polyp base (black dotted box) 24 h after 
tamoxifen injection. g–i, Representative H & E staining of the injured or 
collapsed polyps on days 1 (g), 3 (h, black arrows), and 5 (I, black dotted circle) 
after DT injection. j, The number of the intact polyps was significantly decreased 
in DT-treated mice (n = 6). k, Immunofluorescent staining indicated the 
colocalization of cleaved caspase 3 (red) and Dclk1 (GFP, green) 12 h after DT 
injection (yellow dotted box), suggesting that DT specifically killed Dclk1+ cells 
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including cells at the polyp base. *P < 0.05. Bars, 50 µm. 
 
Fig. 6. Dclk1 is a marker for TSCs rather than NSCs in the intestine. 
a, b, Model for the role of Dclk1 in the normal intestine (a) and tumors (b). (a) 
Most Dclk1+ cells (green) are postmitotic and shed within a few weeks (top), 
whereas Lgr5+ NSCs (dark blue) continuously produce their progeny (pale blue) 
in the intestine (bottom). (b) Dclk1 is expressed in Lgr5+ TSCs (dark purple) that 
continuously produce tumor progeny (light purple). d, Model for the antitumor 
therapy targeting Dclk1+ cells. (1) Targeting Dclk1+ cells (green) does not cause 
mucosal damage to the normal intestine. (2) Elimination of TSCs marked by 
Dclk1 (dark purple) leads to the tumor collapse. 
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Mice. Dclk1-creERT2-IRES-EGFP mice were generated by high-fidelity 
polymerase chain reaction (PCR) from genomic BAC clone RP23-132B14, 
2.5-kilobase (kb) upstream of the ATG start codon of the mouse Dclk1 gene and 
6.1 kb downstream of the end of exon 2. After all components were sequence 
verified, these Dclk1 flanking arms were cloned into pBluescriptII SK+ plasmid 
containing the creERT2-IRES-EGFP cassette, as depicted in Supplementary 
Figure 2. The expression construct (25 µg) was linearized and transfected into 
C57/BL6 mouse embryonic stem (ES) cells by electroporation. 
Neomycin-resistant recombinant ES clones were selected in the medium 
containing G418 for 7 days. A total of 231 recombinant ES clones were 
transferred into 96-well plates and cultured to 70% confluence. Plates were then 
duplicated, one cryopreserved, and one continued in culture to 100% confluence 
for DNA isolation. DNA from all clones was screened for correct targeting by 
long PCR with primers flanking the 5′ short arm. All positive clones and randomly 
selected negative clones were then confirmed by Southern blotting using the 5' 
and 3' probes indicated in Supplementary Figure 2. Six positive clones were 
thawed, expanded and injected into Balb/c blastocysts using standard 
procedures. Male chimeras born after transplantation of the blastocysts into ICR 
foster mothers were subsequently mated with C57BL/6 females, and germline 
transmission was confirmed by screening offspring for the presence of the 
expression cassette in the Dclk1 locus by PCR. The neomycin selection 
cassette was later excised in vivo by crossing with FLP mice. Rosa26R mice, 
Rosa26-iDTR mice, Lgr5-EGFP-IRES-creERT2 mice, and ApcMin/+ mice were 
obtained from the Jackson Laboratory. Generation of Catnb1lox(ex3) mice was 
carried out as described previously 26. All experiments were approved by the 
animal research committee of Kyoto University and performed in accordance 
with Japanese government regulations. 
 
Tamoxifen injection. For lineage tracing experiments in normal tissues and 
polyps, >8-week-old Dclk1creERT2/+; Rosa26R mice or 14-week-old Dclk1creERT2/+; 
Rosa26R; ApcMin/+ mice were injected intraperitoneally with 200 µl of tamoxifen 
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(Sigma) in corn oil at 20 mg ml−1. For tumor formation experiments, >8-week-old 
Lgr5creERT2/+ or Dclk1creERT2/+; Catnblox(ex3)/+ mice were injected with the same 
dose of tamoxifen. For ablation experiments of Dclk1+ tumor cell ablation 
experiments, 14-week-old Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ mice 
were injected with the same dose of tamoxifen. 
 
Diphtheria toxin (DT) injection. DT was generously provided by Professor K. 
Kohno. Fourteen-week-old Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ mice 
were injected intraperitoneally with 100 ng DT in PBS. In the single DT injection 
protocol, DT was given 24 h after tamoxifen administration. In the multiple DT 
injection protocol, DT was given 3 times daily with 8 h interval for 3 days, and the 
final injection was applied 24 h after tamoxifen administration. It has been 
reported that the serum concentration of DT which we used in our experiments 
decreased to <15% of the maximum concentration at 24 h after the injection 30. 
To support the notion that Dclk1+ cells were specifically killed by DT and that 
their progeny was unaffected by DT, which might persist until later time points, 
we injected 15 ng of DT (15% of the dose we used in the ablation experiment) to 
Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ mice. Then, the number of blue 
cells in the normal intestine and blue polyps was not decreased after DT 
injection (Supplementary Figure 16), indicating that Dclk1+ cells were not killed 
by this low-dose DT protocol. This finding suggested that a single injection of 
100 ng DT did not have a significant effect after the next day of DT injection in 
our ablation model. 
 
Injury models. Injury experiments were performed using >8-week-old mice. For 
irradiation-induced injury model, mice were treated with 8 Gy irradiation. For 
dextran sodium sulfate (DSS)-induced colitis model, mice were treated with 
2.0% DSS (MP Biomedicals) given in drinking water for 7 consecutive days. In 





Histological analysis. For histological analysis, mouse organs were isolated 
and fixed overnight in 4% paraformaldehyde (PFA), embedded in paraffin, and 
sectioned at a thickness of 3-5 µm. Sections were then deparaffinized, 
rehydrated, and stained with hematoxylin and eosin (H & E). For 
immunohistochemistry, sections were incubated with primary antibody overnight 
and with the biotinylated secondary antibody, followed by incubation with avidin 
biotin–peroxidase complex (Vector Labs), labeled with peroxidase, and colored 
with diaminobenzidine substrate (Dako). For immunofluorescence, sections 
were incubated with the primary antibodies overnight at 4°C and washed again 
with PBS. Washed sections were treated with fluorescence-conjugated 
secondary antibodies (Invitrogen) for 1 h. For immunofluorescent analysis on 
Lgr5 expression, we had immunostained Lgr5-positive cells with anti-GFP 
antibodies using Lgr5EGFP-IRES-CreERT2 mice. Immunohistochemical analysis of 
human samples was carried out by the same procedure as described above. For 
immunocytochemistory, sorted tumor cells were attached to the slide glasses 
using CytoSpin (Thermo Scientific). Sections were fixed with acetone/methanol 
(3:7), permeabilized with PBS containing 0.1% Tween20 (Sigma), incubated 
with the primary antibodies overnight at 4°C, and treated with 
fluorescence-conjugated secondary antibodies (Invitrogen) for 1 h. Primary 
antibodies included rabbit anti-mouse Dclk1 (1:200; Abcam), mouse anti-human 
Epcam (1:100; Cell Signaling Technology (CST)), mouse anti-human Ki67 
(1:100; Dako), rat anti-mouse Ki67 (1:100; Dako), mouse anti-PCNA (1:100; BD 
Biosciences), rabbit anti-mouse Muc2 (1:50; Santa Cruz), rabbit anti-mouse 
chromogranin A (1:200; Santa Cruz), rabbit anti-human lysozyme (1:200; Dako), 
mouse anti-human β-catenin (1:100; BD Biosciences), rabbit anti-mouse 
cleaved caspase3 (1:100; CST), and chicken anti-mouse GFP (1:1000, Abcam). 
For proliferation assays using BrdU (Fig. 1g, h, and Fig. 3a–c), 300 µl of BrdU 
(Roche) was injected 2 h before the mice were killed. For BrdU pulse and chase 
study (Supplementary Fig. 8), 300 µl of BrdU was injected into 14-week-old 
ApcMin/+ mice 3 times at 3 h interval. Tissues or sorted tumor cells were stained 
using 5’-Bromo-2’-deoxyuridine Labeling & Detection Kit as recommended by 
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the manufacturer (Roche). TUNEL was performed using In Situ Cell Death 
Detection Kit, TMR red (Roche). 
 
β-galactosidase (LacZ) staining protocol. Organs were isolated and 
immediately incubated for 2 h in a 20-fold volume of ice-cold fixative solution 
(PBS containing 4% PFA, 5 mM EGTA, 2 mM MgCl2, 0.2% glutaraldehyde, and 
0.02% NP40) at 4°C on a rolling platform. Small intestine and colon were first 
cleaned by flushing with PBS to remove feces. The fixative was removed and 
the tissues washed twice in PBS for 20 min at room temperature (20°C) on a 
rolling platform. β-galactosidase substrate (PBS containing 5 mM K3F(CN)6, 5 
mM K4Fe(CN)6·3H2O, 2 mM MgCl2, 0.02% NP40, 0.1% sodium deoxycholate, 
and 1 mg ml–1 X-gal) was then added and the tissues incubated in the dark 
overnight at room temperature. The substrate was removed and the tissues 
washed twice in PBS for 20 min at room temperature. The tissues were then 
fixed overnight in a 20-fold volume of 4% PFA in PBS at 4°C in the dark on a 
rolling platform. The PFA was removed and the stained tissues were transferred 
to tissue cassettes and paraffin blocks prepared using standard methods. Tissue 
sections (5 µm) were prepared and counterstained with nuclear fast red (KPL). 
 
Polyp dissociation, flow cytometry, and cell sorting. Mouse intestinal 
adenomas were freshly isolated from the small intestines of Dclk1creERT2/+; 
ApcMin/+ or Lgr5creERT2/+; Catnblox(ex3)/+ mice. The adenoma tissue was minced and 
incubated with digestion buffer (Dulbecco’s modified Eagle medium with 10% 
FCS, penicillin/streptomycin (Invitrogen), 1 mg/mL collagenase type 11 (Sigma), 
and DNase I (1 units/μl) for 20 min at 37°C. After the incubation, cells were 
filtered through a 40-μM mesh, shaken vigorously, and incubated with PBS 
containing 2 mmol/l EDTA for 20 min at 4°C. The dissociated cells were fixed 
with formalin, permeabilized with perm/wash buffer (BD Biosciences), and 
incubated with antibodies against Dclk1, CD44, CD133, Bcl2, and Cox-1 on ice 
for 30 min. Cells stained with primary antibodies received secondary staining 
with fluorescence-conjugated antibodies. Labeled cells were run on a FACSAria 
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II (BD biosciences), and analyzed using the FlowJo software (version 7.6.1, Tree 
Star). To obtain Lgr5+ tumor cells, GFP-expressing cells were sorted by 
FACSAria II. Dead cells were labeled with PI or 7-AAD and excluded from the 
analysis. The antibodies used for flow cytometry included rabbit anti-mouse 
Dclk1 (1:100; Abcam), rat anti-mouse CD44 (1:100; Abcam), rat anti-mouse 
CD133 (1:100; Abcam), mouse anti-human Bcl2 (1:100; Abcam), and goat 
anti-mouse Cox-1 (1:100; Santa Cruz). 
 
RNA isolation and quantitative RT-PCR. RNA was extracted from the sorted 
tumor cells in small intestinal polyps of Dclk1creERT2/+; ApcMin/+ mice using 
RNeasy Micro Kit (Qiagen) according to the manufacturer’s instructions; then, 
single-stranded cDNA was synthesized using Superscript III (Invitrogen). 
Quantitative PCR was performed using the Light Cycler FastStart DNA Master 
SYBR Green 1 kit (Roche Diagnostics). The amplification conditions included 10 
seconds of denaturation at 95°C, 5 seconds of annealing at 57°C, and 10 
seconds of extension at 72°C for a total of 45 cycles. 
 
Human subjects. Analyses for human subjects were approved by the ethical 
committee of Kyoto University Hospital, and written informed consent was 
obtained from all the subjects. Tissue samples were obtained from 80 patients 
with colorectal cancer during surgery at Kyoto University Hospital; any 
information identifying subjects has been omitted. Samples were processed for 
immunohistological studies after fixing in 10% formalin. The percentage of 
Dclk1+ cancer cells was determined by three authors (Y.N., H.S., and K.Kanda) 
based on the staining of 10 randomly selected high power fields (×400) for each 
sample. 
 
Statistics. All values are presented as mean ± S.D. unless otherwise stated. 
The two-tailed Student’s t-test or chi-square test, and Fisher's exact test were 
used for statistical analysis. P-values of <0.05 were considered significant. 
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Supplementary Figure 1. Immunohistochemical analyses of Dclk1 expression 
in mice and humans. (a) Immunohistochemistry of Dclk1in murine normal small 
intestine. Dclk1+ cells (black arrowheads) were observed in both the crypts and villi. 
(b) The number and localization of Dclk1-stained cells per 1000 crypt-villus units 
showed Dclk1+ cells were observed most frequently at the lower crypt (n = 3). 
Crypt-villus junction (CVJ) indicated the boundary between the higher crypt and the 
villus. (c) Immunohistochemistry of Dclk1 in the polyps of ApcMin/+ mice. The black 
dotted box shows a magnified view of Dclk1+ tumor cells. (d–j) Six representative 
cases of human CRCs stained with Dclk1 (d–j). The expression of Dclk1 was 
observed in both human normal colonic crypts (d) and CRCs (e–g). The black 
dotted boxes show magnified views of Dclk1+ cells (black arrows). The proportion of 
Dclk1+ cancer cells was determined in 10 randomly selected high power fields 
(×400) for each sample, and the frequency of Dclk1+ cells in CRC specimens 
ranged from approximately 1 per 2 × 102 to 1 per 5 × 103. Double immunostaining of 
Dclk1 (green) and Epcam (red) showed that Dclk1 was expressed in cancer cells 
(h). Dclk1+ cancer cells (green) occasionally expressed the proliferation markers 
PCNA (i, red) or Ki67 (j, red). The yellow dotted boxes show magnified views of 
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Supplementary Figure 2. Generation of Dclk1-creERT2-IRES-EGFP mice. (a) A 
creERT2-IRES-EGFP cassette was cloned into the first ATG site in exon 2 of the 
mouse Dclk1 gene. The expression construct was linearized and transfected into 
C57/BL6 mouse embryonic stem (ES) cells by electroporation, and 
neomycin-resistant recombinant ES clones were selected. DNA from all clones was 
screened for correct targeting by PCR with primers flanking the 5′ short arm (not 
shown). All positive clones and randomly selected negative clones were then 
confirmed by Southern blotting using the 5′ and 3′ probes. The neomycin selection 
cassette was later excised in vivo by crossing with FLP mice. Efficient cre 
expression was given priority, while several splice variants of Dclk1 that may 
compensate for the function of Dclk1 remained in Dclk1-creERT2-IRES-EGFP 
(Dclk1creERT2/+) mice 33,34. (b) Representative Southern blotting using the 5′ and 3′ 
probes. (c) Immunofluorescent staining demonstrated GFP (green) strictly 


























































Supplementary Figure 3. Dclk1creERT2/creERT2 mice showed no difference in the 
intestinal structure compared with wild-type mice. (a) Immunohistochemistry 
for Dclk1 in the small intestine (left) and colon (right) of wild-type (WT) and 
Dclk1creERT2/creERT2 mice. Although Dclk1 staining was not detected in 
Dclk1creERT2/creERT2 mice, no difference in the number of crypts and height of villi was 
shown compared with WT mice. (b) Immunohistochemistry for Ki67 showed no 
difference in proliferative state between WT and Dclk1creERT2/creERT2 mice. (c) Alucian 
blue staining showed no difference in the number of goblet cells between WT and 
Dclk1creERT2/creERT2 mice. (d–f) Immunohistochemistry for villin (d), chromogranin A 
(e), and lysozyme (f) demonstrated no difference in the number of enterocytes, 
enteroendocrine cells, and Paneth cells between WT and Dclk1creERT2/creERT2 mice. 














Supplementary Figure 4. Dclk1+ cells were different from other differentiated 
cells in the intestine. (a–d) Double-staining against Dclk1 (GFP) and other 
differentiated cell markers (Muc2, lysozyme, chromogranin A, and villin) in 
Dclk1creERT2/+ mice are shown. Dclk1 (GFP, green)+ cells were different from 
Muc2-positive goblet cells (a, red), lysozyme-positive Paneth cells (b, red), and 
chromogranin A-positive enteroendocrine cells (c, red). Dclk1 (GFP, green)+ cells 
showed stronger immunoreactivity toward villin (red) compared with enterocytes 
(d). Bars, 50 µm. 










Supplementary Figure 5. Cre-mediated cell tracking of Dclk1+ cells in normal colon. (a) 
Representative LacZ staining (black dotted circles) against colon of Dclk1creERT2/+; Rosa26R 
mice on days 1, 7, and 14 after a single tamoxifen injection. Bars, 50 µm. (b) Number and localization
of blue-labeled Dclk1+ cells per 1000 crypts after a single tamoxifen injection (n = 3 for each time point).
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Supplementary Figure 6. Dclk1+ cells rarely showed stemness, even during regeneration 
after mucosal injury. (a) Treatment schedule of irradiation (IR)-induced mucosal injury. 
Dclk1creERT2/+; Rosa26R mice were treated with 8 Gy IR on day 0, and the small intestine analyzed 
on days 0 (6 h after IR), 7, and 14. (b–d) Blue-labeled Dclk1+ cells (black dotted circles) were 
detected on days 0 (b) and 7 (c). On day 14, extremely small proportion of “blue stripes” was detected 
(d). (e) Treatment schedule of dextran sulfate sodium (DSS)-induced mucosal injury. Dclk1creERT2/+; 
Rosa26R mice were treated with 2.0% DSS from days 0–7, and colons analyzed on days 7 
(immediately after final DSS), 10, and 14. (f–i) Blue-labeled Dclk1+ cells (black dotted circles) were 
detected on days 7 (f) and 10 (g), and blue stripes were rarely detected adjacent to the ulcer (U) on 
day 14 (h, i, yellow arrow). (j) The number of blue stripes was counted in the whole intestine of 
untreated (ctrl) and IR-treated mice (IR; n = 10). (k) The number of blue stripes was significantly 
larger in the whole colon of DSS-treated mice (DSS; n = 10) than in that of control mice. *P < 0.05. 
Bars, 50 µm.
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Supplementary Figure 7. Dclk1+ tumor cells generated “blue polyps” in 
whole small intestine. (a) Macroscopic images of blue polyps in whole 
small intestine of Dclk1creERT2/+; Rosa26R; ApcMin/+ mice on day 7 after 
tamoxifen induction. ‘‘Blue polyps” were observed throughout the small 
intestine, although most abundant in the duodenum. (b–d) Representative 




















































Supplementary Figure 8. The turnover rate of tumor cells was approximately 
7 days. (a) Representative LacZ staining on days 1, 4, and 7 after a single 
tamoxifen injection in the polyps of Lgr5creERT2/+; Rosa26R; ApcMin/+ mice. 
Descendant tumor cells from Lgr5+ cells occupied the whole polyp within 7 days. 
Uniformly-labeled blue polyps were rarely observed in Lgr5 creERT2/+; Rosa26R; 
ApcMin/+ mice, because IRES sequence between Lgr5 promoter and creERT2 may 
lower the expression efficiency of creERT2 in Lgr5 creERT2/+ mice. (b) Treatment 
schedule for BrdU pulse and chase. ApcMin/+ mice were treated with BrdU 3 times a 
day and the polyps were analyzed by immunohistochemistry of BrdU on days 1, 4, 7, 
and 10 after the treatment. (c) The number of BrdU-labeled tumor epithelial cells 
was counted in the polyps at each time point (n = 3). The proportion decreased 
rapidly and >95% of BrdU+ tumor epithelial cells disappeared after 7 days chase. (d) 
Representative immunofluorescent staining of BrdU (red) in the polyps on days 1, 4, 
and 7. E-cadherin (green) was used for counter-staining to identify tumor epithelia. 











































Supplementary Figure 9. ApcMin/+; Dclk1creERT2/creERT2 mice 
showed no difference in the number and size of polyps 
compared with ApcMin/+ mice. (a, b) Representative 
H & E staining of small intestinal polyps of ApcMin/+ (a) and 
ApcMin/+; Dclk1creERT2/creERT2 (b) mice. (c) There was no 
difference in the total number of small intestinal polyps 
between ApcMin/+ mice and ApcMin/+; Dclk1creERT2/creERT2 
mice. (d) The number of small intestinal polyps in ApcMin/+ mice 
and ApcMin/+; Dclk1creERT2/creERT2 mice was counted by 
polyp size fraction. No significant difference was observed 
between these mice, which seemed to be different from a 
previous report in which Dclk1 knockdown resulted in tumor 
regression in vitro 35. This might be due to Dclk1 splice variants 
remaining in the Dclk1-creERT2 knock-in allele and homologues 
of Dclk1 which can compensate for the function of Dclk1 (see 
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Supplementary Figure 10. Dclk1+ tumor cells occasionally 
expressed proliferation markers in the polyps of ApcMin/+ mice.
(a) Double-immunostaining demonstrated that Dclk1+ cells (green) 
did not colocalize with nuclear β-catenin staining (red) in the normal 
intestine. (b) Nuclear β-catenin (red) was detected in most Dclk1+ 
tumor cells (green) in the polyps of ApcMin/+ mice. (c, d) Dclk1+ 
tumor cells (green) occasionally colocalized with BrdU (c) and Ki67 (d) 
in the polyps of ApcMin/+ mice. Bars, 10 μm.
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Supplementary Figure 11. Induced stabilization of β-catenin in Dclk1+ cells did not cause 
polyp formation. (a) Experimental strategy of tamoxifen-inducible Cre-mediated stabilization of 
β-catenin in Lgr5creERT2/+ or Dclk1creERT2/+; Catnblox(ex3)/+ mice. (b, c) Macroscopic image 
(b) and histology (c) of small intestine in Lgr5creERT2/+; Catnblox(ex3)/+ mice showed development 
of numerous polyps 40 days after tamoxifen injection. (d) Immunofluorescent staining of Lgr5 (GFP, 
green) and β-catenin (red) in the polyps of Lgr5creERT2/+; Catnblox(ex3)/+ mice 40 days after 
injection. Lgr5+ tumor cells positive for nuclear β-catenin were observed at the polyp base. (e, f) 
Macroscopic image (e) and histology (f) showed no detectable polyp in the small intestine of 
Dclk1creERT2/+; Catnblox(ex3)/+ mice even 45 days after tamoxifen injection. (g) Two days after 
tamoxifen injection, Dclk1+ cells (green) showed nuclear accumulation of β-catenin (red) in the 






Supplementary Figure 12. Dclk1+/Lgr5+ cells were detected in the polyps of 
Lgr5creERT2/+; Catnblox(ex3)/+ mice. (a–c) Immunofluorescent analyses on the 
expression of Dclk1 (red) and Lgr5 (GFP, green) in Lgr5creERT2/+; Catnblox(ex3)/+ 
mice. Yellow dotted boxes showed magnified images. Dclk1+/Lgr5+ tumor cells were 
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Supplementary Figure 13. FACS analyses of intestinal 
tumor cells on the basis of Dclk1 and Lgr5 expression.
(a) Flow cytometry sorted tumor cells on the basis of Dclk1 
and GFP expression in Dclk1creERT2/+; ApcMin/+ mice. 
GFP strictly colocalized with anti-Dclk1 staining in the polyps. 
(b) qRT-PCR demonstrated that mRNA expression of the 
sequence targeting the creERT2-IRES-EGFP cassette was 
restricted to Dclk1–GFP+ cells. (c) Flow cytometry sorted tumor 
cells on the basis of Lgr5-GFP expression in Lgr5creERT2/+; 
Catnblox(ex3)/+ mice 40 days after tamoxifen injection. 
The sorted Lgr5-positive or -negative tumor cells were 
collected for immunocytostaining. (d) Flow cytometry showed 
that the expression of Cox-1 was elevated in each population 
of Dclk1+ fractions.




Supplementary Figure 14. Intense ablation of Dclk1+ cells by multiple DT 
injection did not cause significant damage to other organs. (a–c) Intense 
ablation of Dclk1+ cells by “3 times daily for 3 days” injections of DT did not 
cause significant damage to the stomach (a), pancreas (b), or gallbladder (c) 








































































































Supplementary Figure 15. DT specifically killed Dclk1+ tumor cells without affecting the 
apoptotic status of other tumor cells in the polyps. (a) The proportion of total cleaved caspase3-
positive apoptotic tumor cells in the untreated control polyps (DT(–)) and in the polyps at indicated 
time points (12 h and 48 h) after DT injection of Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ mice. 
Tamoxifen was injected 24 h before DT injection. The increase of the proportion of cleaved caspase3-
positive cells at early time point (12 h) reflected the apoptosis of Dclk1+ cells (see panel b). (b) The 
proportion of apoptotic cells in Dclk1– tumor cells was not affected by DT treatment (left). On the other 
hand, the proportion of apoptotic cells in Dclk1+ tumor cells showed that most Dclk1+ tumor cells 
underwent apoptosis at early time point (12 h) after DT injection (right). Apoptotic Dclk1+ tumor cells 
were hardly detected at later time point (48 h). (c) Immunofluorescent staining of cleaved caspase 3 
(red) and Dclk1 (GFP, green) 48 h after DT injection. Dclk1+ tumor cells were hardly detected in the 
collapsing polyps, suggesting that DT eliminated Dclk1+ tumor cells in early time points after DT 































Supplementary Figure 16. Dclk1+ cells were not sufficiently eliminated by 
low-dose DT protocol. (a–c) To examine whether DT had a significant effect 
after the next day of the injection, low-dose (15 ng) DT was injected to 
Dclk1creERT2/+; Rosa26R; ApcMin/+; Rosa26iDTR/+ mice 24 h after tamoxifen 
administration, and mice were analyzed 5 days after low-dose DT injection 
(n = 5). Blue-labeled Dclk1+ cells (black dotted circles) were not significantly 
decreased by low-dose DT treatment (a). Fully labeled blue polyps could be 
detected in low-dose DT-treated mice (b). The number of the intact polyps was 
not decreased in low-dose DT-treated mice (DT(+)) compared to untreated 
controls (DT(–)) (c). Bars, 50 µm.
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Supplementary Table. Primers used in quantitative RT-PCR. 
 
Primer name Sequence 
mouse GAPDH-Forward 5'- AGGTCGGTGTGAACGGATTTG -3' 
mouse GAPDH-Reverse 5'- TGTAGACCATGTAGTTGAGGTCA -3' 
sequence targeting creERT2-IRES-EGFP cassette-Forward 5'- AGAACGGCATCAAGGTGAAC -3' 
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